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ABA  Abamectin — non-persistent ML 
BZLV  Combination treatment of BZ+LEV 
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MOX  Moxidectin — persistent ML 
MPL  Monepantel (an AAD) 
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Abstract 
Objective  To compare the risk of different treatment scenarios on selecting for 
anthelmintic resistance on Australian sheep farms. 
 
Design  A computer simulation model predicted populations of Trichostrongylus 
colubriformis, Haemonchus contortus or Teladorsagia (Ostertagia) circumcincta, and the 
frequency of anthelmintic resistance genes. 
 
Method  Nematode populations and the progression of drug resistance for a variety of 
treatment options and management practices in sheep rearing areas of WA, VIC and NSW 
were simulated. A scoring system was devised to measure the success of each option in 
delaying resistance to each anthelmintic and in controlling nematode populations. 
 
Results   The best option at all sites was combining the new anthelmintic (monepantel) 
with a triple mixture of benzimidazole, levamisole and abamectin (COM). The next best 2 
 
option was: in NSW, rotation at each treatment between monepantel, moxidectin and COM; 
in VIC, rotation at each treatment between monepantel and COM; and in WA, rotation at each 
treatment between monepantel (used in winter) and COM or moxidectin (used in summer-
autumn). In WA, rapid selection for resistance occurred as a consequence of summer-autumn 
treatments; however, if a small percentage of adult stock were left untreated then this 
selection could be greatly reduced. Despite purposely assuming relatively high resistance to 
benzimidazole and levamisole, COM was still effective in controlling worms and delaying 
resistance. 
 
Conclusions  Due to cost constraints, it may not be feasible or profitable for producers to 
always use the combination of all drugs. However, the second and third best options still 
considerably slowed the development of anthelmintic resistance. 
 
Key words: anthelmintic resistance, monepantel, grazing management, sheep, nematode 
control, simulation model 
 
Introduction 
The release of the first compound from the new amino-acetonitrile derivative (AAD) 
anthelmintics in New Zealand
1,2 (monepantel, MPL; Zolvix
®, Novartis Animal Health Inc., 
Switzerland) is an opportune time to examine how best to use a new class of anthelmintics on 
Australian sheep farms. Important considerations include both the rate of development of 
anthelmintic resistance and the effectiveness of control options in reducing the production 
losses from nematodes. Laboratory and field studies can contribute useful information, but 
they take many years to conduct and are expensive. Consequently, the only practical way to 
achieve this analysis in the short-term is by using computer models that simulate populations 
of gastro-intestinal parasites in grazing ruminants.
3 Generally models
4-6 simulate either mono-
specific or ‘general’ nematode
7 infections rather than multiple parasite species. The 
complexity resulting from combining a number of single species models may only add to an 
overload of information, without adding to the understanding gained from simply using the 
models individually. To simplify interpretation from a multi-species model we developed a 
single measure, for a control option, which reflects the development of drug resistance to all 
broad-spectrum anthelmintic classes as well as the ability to control the major nematode 
species at a particular site. 
 
Nematode control regimens used in the main sheep farming areas of Australia were modelled 
and a variety of drug use options were examined for each area. The regimens modelled were 
relatively prescriptive systems; Barger
8 previously pointed out that before implementing a 
control option, farmers will consider effectiveness, cost and ease of applying the strategy, 
with the ‘sustainability’ of an option likely to be a lower order priority. Thus, as more 
complex systems are less likely to be maintained by producers, relatively simple and 
straightforward regimens, considered likely to impede the development of drug resistance 
were tested. While routine faecal worm egg count monitoring to optimise treatment times are 
recommended, it has been adopted by only a minority of sheep producers to date. 
 
A simple sustainable way to delay selection for anthelmintic resistance is to apply a 
combination treatment of effective unrelated drugs.
3,6,9-12 This is not always possible because 
resistance to the current anthelmintics may be present on a farm, or there is a reluctance by 
producers to use multi-active treatments when a single active is still effective or cheaper. 3 
 
Therefore, the use of a new drug class (in this case, the AADs represented by MPL) in 
combination with existing drugs with a relatively high level of resistance (i.e. benzimidazole 
[BZ] and levamisole [LEV]) or moderate level of resistance (i.e. abamectin [ABA]), and the 
rotation of the new drug with other anthelmintics (e.g. moxidectin [MOX] and COM; where 
COM is a mixture of BZ+LEV+ABA), was studied. By exploring the potential outcomes of 
these options for all anthelmintics sound advice will be available to graziers; certain options 
may involve sacrificing some of MPL lifespan to prolong the useful life of other 
anthelmintics. 
 
When a new anthelmintic class is released, the expected resistance (R)-allele frequency is 
likely to be very low, say one in a million, and resistance would take a relatively long time to 
develop. Additionally, the genetics of inheritance for resistance are unknown. In this study, 
the initial MPL R-allele frequency was purposely set at a level higher than that expected for a 
new drug so that resistance to MPL would artificially develop in a relatively short time when 
used alone. Resistance was also assumed to be co-dominant so that resistance would develop 
in a shorter period than if resistance was a recessive trait. With these measures, the options 
that delayed resistance could be more readily identified by computer simulation. Monepantel 
here is representative of any new drug and the simulations can be refined when information 
about MPL resistance is obtained; however, it is important that various drug management 
options are explored before resistance emerges. 
 
Materials and Methods  
Local weather data and management practices for self-replacing Merino flocks at Kojonup 
(Western Australia, WA), Hamilton (Victoria, VIC) and Glen Innes (New South Wales, 
NSW) were used to simulate: T. circumcincta and T. colubriformis populations at the first two 
sites, and H. contortus and T. colubriformis populations at the NSW site. The assumptions 
required to simulate the evolution of anthelmintic resistance are described in detail in 
Appendix 1. Monepantel and macrocyclic lactone (ML) resistance were simulated 
independently. However, because the model
5 can only simulate resistance to three drugs 
simultaneously, resistance to BZ and LEV was modelled as a single drug given as a 
combination (denoted as BZLV, Appendix 1). The initial R-allele frequency for MPL was 
0.001% for Trichostrongylus and Haemonchus, and 0.003% for Teladorsagia. The R-allele 
frequency for MPL was set such that MPL resistance developed in no more than 10 years 
when MPL was used exclusively under the conditions simulated. Resistance to ML was 
assumed to be common, and to BZLV very common, and so the R-allele frequencies for ML 
and BZLV were set at 3% and 40%, for all species, respectively. The models described by 
Barnes and Dobson
5 for T. colubriformis and Roberts and Swan
4 for H. contortus were 
modified to predict single or concurrent populations of T. circumcincta, T. colubriformis and 
H. contortus in sheep and on pasture.
13 All simulations were run for 20 years. 
 
Treatment options simulated 
The following four options were simulated at all sites: 1. MPL+COM; 2. MPL/COM rotation; 
3. MPL/MOX rotation; 4. MPL/COM/MOX rotation. The effect of changing the sequence of 
treatments within a rotation was also examined for options 2-4 in WA. For option 1, at each 
scheduled anthelmintic treatment a combination of MPL and COM was applied. Drug 
rotations (options 2-4) were within the annual treatment cycle and not based on a calendar 
year (Tables 1-3). Four ‘control’ treatments were also simulated, against which the 4 
 
effectiveness of the four treatment options to reduce nematode populations and select for drug 
resistance could be measured. The control treatments were: Untreated; MPL only; COM only; 
and MOX only. 
 
Simulations of all the drug treatment options were then repeated, but with 1 to 10% of adult 
stock not receiving any anthelmintic treatment. All lambs received their scheduled treatments 
in these simulations. This was performed to assess the effects of leaving some nematodes not 
exposed to anthelmintics on selection for drug resistance and effectiveness of parasite control. 
The details of this analysis are reported with the description of the multi-species model
13 but 
are briefly discussed in the results because refugium is a key issue, particularly in WA. 
 
‘Summer-autumn drenching’ in Western Australia 
The management schedule is set out in Table 1. The ewes were not given any anthelmintic 
treatment while on paddock 3, with the aim to provide a relatively unselected nematode 
population (i.e. ‘refugia’) for lambs that grazed this paddock in May. The drug sequence used 
for the rotation options (2-4) are shown in Table 1. Additional simulations for options 2-4 
were run where a single MPL treatment was given to ewes in April and to lambs in December 
(options 2a-4a), and the alternate drugs were used for the other treatments. This was done to 
evaluate the impact of changing the drug sequence in an environment with a harsh, dry 
summer, such as Kojonup. 
 
Table 1 Basic management and anthelmintic treatments applied to ewes and lambs in WA. 
      OPTIONS: 
EWES  WEEK  ACTION  2  3 
a4  2a  3a 
a4a 
Early Jul  1  Lambing on paddock 1         
Late Dec  25  Move to paddock 3           
Early Apr  40  Drench move 
to paddock 1 
COM  MOX 
aM/C  MPL  MPL  MPL 
Early Jun  49  Drench  MPL  MPL  MPL  COM  MOX 
aM/C 
LAMBS  AGE  ACTION              
Early Jul  1  Born on paddock 1           
Early Oct  14  Drench move 
to paddock 2 
MPL  MPL  COM  COM  MOX  COM 
Late Dec  25  Drench  COM  MOX  MOX  MPL  MPL  MPL 
Early May  44  Move to paddock 3           
Early Jun  48  Drench  MPL  MPL  MPL  COM  MOX  MOX 
Late Jun  52  Remove from system           
a M/C treatment with MOX or COM to ewes was alternated annually for option 4 and 4a. 
 
‘Wormplan’ in Victoria 
The management schedule and sequence of drug use for options 2-4 in VIC are shown in 
Table 2. In late October, dry adult stock that grazed paddock 2 (not shown in Table 2) were 
moved to paddock 3, three weeks before lambs were weaned onto paddock 2. In early 
February, they were interchanged with the weaners on paddock 2. The dry adults were 
drenched in mid-November and early February. Note for option 4, the dry adults were not 
given a COM treatment as they only received two treatments per annum, and it was assumed 
they would receive the same anthelmintic when the ewes were treated. 5 
 
 
Table 2 Basic management and anthelmintic treatments applied to ewes and lambs in VIC. 
EWES  WEEK  ACTION   Option 2  Option 3  Option 4 
Mid Aug  1  Lambing on paddock 1       
Mid Nov  13  Drench (weaning)  COM  MOX  MOX 
Early Feb  24  Drench  MPL  MPL  MPL 
Late Jul  49  Drench (pre-lamb)  COM  MOX  COM 
LAMBS  AGE  ACTION        
Mid Aug  1  Born on paddock 1       
Mid Nov  13  Drench and move to paddock 2  COM  MOX  MOX 
Early Feb  24  Drench and move to paddock 3  MPL  MPL  MPL 
Late May  41  Drench  COM  MOX  COM 
Mid Aug  52  Remove from system       
 
‘Worm Kill’ in New South Wales 
The basic treatment schedule for options 2-4 is mainly for short-acting anthelmintics (Table 
3). For the MOX only control regimen, ewes received pre-lambing, weaning, mid-February 
and mid-April treatments; lambs received late October, mid-December, mid-February, mid-
April and late August treatments. More treatments are given here than in WA or VIC because 
of the risk posed by H. contortus. 
 
Table 3 Basic management and worm control operations applied to ewes and lambs in NSW. 
EWES  WEEK  ACTION   Option 2  Option 3  Option 4 
Mid Sep  1  Lambing on paddock 1        
Mid Dec  13  Drench (weaning)  MPL  MPL  MPL 
Early Feb  20  Drench  COM  MOX  MOX 
Mid Mar  26  Drench  MPL  nt  COM 
Late Apr  33  Drench  COM  MPL  MPL 
Late Aug  49  Drench (pre-lamb)  MPL  MOX  MOX 
LAMBS  AGE  ACTION  
     
Mid Sep  1  Born on paddock 1       
Late Oct  7  Drench  COM  MOX  COM 
Mid Dec  13  Drench and move to paddock 2  MPL  MPL  MPL 
Early Feb  20  Drench  COM  MOX  MOX 
Mid Mar  26  Drench  MPL  MPL  COM 
Late Apr  33  Drench  COM  MOX  MPL 
Late Jun  41  Drench  nt  nt  MOX 
Late Aug  49  Drench  MPL  nt  nt 
Mid Sep  52  Remove from system       
nt = no treatment. 
 
Estimating host mortalities 
See Dobson et al.
13 for a full description of how deaths from concurrent nematode infections 
were estimated; a brief summary follows. Lethal parasite burdens in lambs and adult sheep 
were assumed to be 50,000, 25,000 and 15,000 for T. colubriformis, T. circumcincta and H. 
contortus, respectively (except lethal H. contortus burden for lambs was set at 10,000). 6 
 
Predicted T. circumcincta and H. contortus worm burdens were converted to T. colubriformis 
‘equivalents’. For example, in lambs total T. colubriformis equivalents was: 
T. colubriformis equivalents = T. colubriformis + 2 x T. circumcincta + 5 x H. contortus. 
The factors used above to convert T. circumcincta (2) and H. contortus (5) to T. colubriformis 
are: (T. colubriformis lethal burden/T. circumcincta lethal burden), and (T. colubriformis 
lethal burden/H. contortus lethal burden), respectively. The predicted nematode burden and 
dispersion parameter (k) of the negative binomial distribution
5 were used to estimate the 
proportion of animals with T. colubriformis equivalents greater than the T. colubriformis 
lethal nematode burden. This proportion of the flock was assumed to die. The mean nematode 
burdens of each species were then adjusted to account for the loss of worms in the heaviest 
infected animals. 
 
Ranking the relative effectiveness of the options 
Two scores were formulated to rate each option on their ability to (a) delay selection for 
resistance, and (b) control nematodes. Scores were then pooled to (c) determine ranks. To 
derive these scores, weights, based on expert opinion
14 were assigned to scale the importance 
of mean nematode (worm) burden (WB), sheep deaths and anthelmintic resistance. Weights 
ranged from 1 = unimportant to 5 = very serious. 
 
(a) For resistance to MPL, ML and BZLV the weights 5, 4.2 and 2.5 were used, respectively. 
To determine the resistance score for each species and option: 
(1) The relative time (RT) to resistance for each drug class (MPL, ML and BZLV) was 
obtained by dividing the time to reach 50% R-alleles by the time to 50% R-alleles when 
resistance developed fastest, e.g. a RT of two for a particular option and drug indicates it took 
twice as long for resistance to develop. 
(2) The RT was converted to a mark from 0 to 100 such that the RT of 1 (fastest time to 
resistance) became 100 and was 0 if 50% R-alleles was not reached in 20 years. 
(3) The mark was then multiplied by the weight (see (a) above) for each drug class, i.e. the 
maximum mark for MPL, ML and BZLV was 500, 420 and 250, respectively. 
(4) The average of the weighted mark was the resistance score for the nematode species and 
option; the higher the score the more rapidly resistance developed. 
 
(b) For the nematode control score, weights of 3.9, 5.0, 3.7 and 3.6 were used for ewe WB, 
ewe death, lamb WB and lamb death, respectively. In addition, weights of 4.5 and 3.5 were 
used for means over years 1-6 and 1-20, respectively. For each species and option the 
nematode control score was determined by: 
(1) Converting the ewe and lamb mean WB and death rates for years 1-6 and 1-20 to a 
percentage of the maximum mean WB and death rate (from the untreated control), i.e. 
provides eight values (2 animal classes * 2 measures * 2 periods). 
(2) The weighted sum (over ewe and lamb using above weights) of percentage WB and death 
rate for years 1-6 and 1-20 was tallied to yield four values. 
(3) The mean of these four values weighted for years was the nematode control score for the 
nematode species and option; the higher the score the worse nematode control was. 
 
(c) Pooling the scores to determine ranks. In each state, species were assigned different 
weights: for T. colubriformis being 4.2, 4.8 and 4.6 in WA, VIC and NSW, respectively; T. 
circumcincta weights were 4.6 in WA and 4.2 in VIC; and in NSW, H. contortus was 4.6. The 
weighted average over the two species for each option in each state was then determined. The 7 
 
total score was the sum of the pooled nematode control and resistance score. Ranks within 
each state were then determined for the options (Tables 4-6). 
 
In summary: The ‘total score’ and ‘rank’ rates the options on their ability to control 
nematodes and delay resistance expressed as a single measure. Tables 4-6 also provide results 
expressed as percentage effectiveness to control nematodes and to delay resistance. 
‘Effectiveness of nematode control’ is the death rate plus nematode burden score for each 
option expressed as a percentage reduction of the score for the untreated controls, which is 
equivalent to ‘efficacy’. ‘Effectiveness to delay resistance’ is the resistance score for each 
option expressed as a percentage reduction from the highest resistance score from the 
treatment controls where each drug was used exclusively. 
 
 
Results 
 
The ‘total score’ (in Tables 4-6) provides a composite estimate of a particular option’s ability 
to control nematodes and delay resistance. From Tables 4-6, option 1 (MPL+COM) 
consistently ranked best because of its superior ability to delay selection for resistance, though 
some of the MOX-rotation treatments showed better worm control (option 4 in NSW and 
options 3 and 4 in VIC). Option 1 is excluded from the site-specific reporting of the results 
below. 
 
Western Australia 
When used solely, resistance to MPL did not develop if the R-allele frequency was less than 4 
and 9 per 10
6 for T. colubriformis and T. circumcincta, respectively. The sequence of drugs 
used for options 2-4 was important; Table 4 gives the results for winter (options 2-4) and 
summer/autumn use of MPL (options 2a-4a). It is clear from this table that it was preferable 
to use a new anthelmintic in winter (i.e. the sequence given for option 2-4 in Table 1) and 
then use COM or MOX at other times, but this generally led to more rapid selection of 
resistance to the drug used in summer or autumn (i.e. when there was little refugia from 
anthelmintics in the external environment). This could be overcome by leaving 1-4% of adult 
ewes untreated (data not shown); the MPL/COM option effectiveness to delay resistance rose 
from 51% to 100% while only declining slightly in its effectiveness to control parasites. More 
detailed analysis of this strategy is published elsewhere.
13 
 
‘Wormplan’ in Victoria 
When used solely, resistance to MPL did not develop if the R-allele frequency was less than 1 
and 10 per 10
6 for T. colubriformis and T. circumcincta, respectively. Here option 2 
(MPL/COM) ranked best and was comparable to MPL+COM. Unlike WA, its ability to delay 
selection for drug resistance was not enhanced even when 10% of adults were left untreated.
13 
Using MPL as the first rather than the second summer treatment had little effect on the 
outcome (data not shown). 
 
‘Worm Kill’ in New South Wales 
When used solely, resistance to MPL did not develop if the R-allele frequency was less than 2 
and 5 per 10
6 for T. colubriformis and H. contortus, respectively. Here option 4 
(MPL/COM/MOX) was the next best option after MPL+COM (Table 6). In the untreated 
control simulation the average deaths per year was 8% (range 2 to 20%) and attributable in 8 
 
approximately equal measure to both T. colubriformis and H. contortus. For years 1-6, i.e. 
prior to resistance fully emerging, mean deaths for the four treatment options and treated 
controls was 1.5% (range between years 0.7 to 2.6%) and regimens using either short- or 
long-acting anthelmintics were effective. 
 
Additional simulations were run in an environment where H. contortus was a more serious 
threat.
13 In this situation, only H. contortus was simulated and deaths in untreated controls 
increased to 28% (range 2 to 81%). For years 1-6, treatment options and controls that 
included MOX reduced deaths to a mean of 5.5% and the MPL/MOX rotation option yielded 
the lowest death rate of 1.1%. For options and controls that only used short-acting 
anthelmintics the death rate in years 1-6 was reduced to 13.9% as the treatment schedule 
(Table 3) provided insufficient short-acting treatments or grazing management to effectively 
control H. contortus in this environment. 
 
Table 4 The effect of seven treatment options simulated in impeding the development of 
anthelmintic resistance and controlling T. colubriformis and T. circumcincta in WA. 
      % Effectiveness  Death  Mean  Mean    Treatment options
b: 
of worm  to delay  rate  worm  resistance  Total  Score  MPL given in 
control  resistance   %
c  score
a  score
a  score  rank  winter 
94  100  0.1  40  0  40  1  1.MPL+COM 
91  51  1.2  54  82  136  2  2.MPL/COM 
92  46  1.5  48  91  139  3  3.MPL/MOX 
93  17  0.5  44  138  182  4  4.MPL/COM/MOX 
            MPL use: summer/autumn 
83  19  9.9  102  136  238  5  4a.MPL/COM/MOX 
82  21  9.9  109  131  240  6  2a.MPL/COM 
83  11  9.8  102  149  250  7  3a.MPL/MOX 
    Highest scores from controls  614  167         
aUnlike % effectiveness, the lower the score the lower the resistance level and worm 
populations. Resistance score is a weighted mean of MPL, ML and BZLV R-alleles. The 
worm score includes host death and worm burden and is a weighted mean of the two species 
involved (see text); 
bOptions are ranked over seven treatments options (i.e. including winter 
and summer/autumn MPL use); 
cMean death rate for lambs and ewes. 
 
Table 5. The effect of four treatment options simulated in impeding the development of 
anthelmintic resistance and controlling T. colubriformis and T. circumcincta in VIC. 
      % Effectiveness  Death  Mean  Mean         
of worm  to delay  rate  worm  resistance  Total  Score   
control  resistance  %
c  score
a  score
a  score  rank  Treatment options 
93  100  0.4  30  0  30  1  1.MPL+COM 
93  100  0.4  30  0  30  2  2.MPL/COM 
94  83  0.2  27  29  56  3  4.MPL/COM/MOX 
94  78  0.2  26  36  63  4  3.MPL/MOX 
    Highest scores from controls  419  167         
aUnlike % effectiveness, the lower the score the lower the resistance level and worm 
populations. Resistance score is a weighted mean of MPL, ML and BZLV R-alleles. The 9 
 
worm score includes host death and worm burden and is a weighted mean of the two species 
involved (see text); 
cMean death rate for lambs and ewes. 
 
Table 6 The effect of four treatment options simulated in impeding the development of 
anthelmintic resistance and controlling T. colubriformis and H. contortus in NSW. 
% Effectiveness  Death  Mean  Mean         
of worm  to delay  rate  Worm  resistance  Total  Score     
control  resistance  %
c  score
a  score
a  score  rank  Treatment options 
77  100  1.8  116  0  116  1  1.MPL+COM 
83  52  0.9  87  81  168  2  4.MPL/COM/MOX 
68  68  2.6  162  54  216  3  2.MPL/COM  
56  58  3.7  223  70  293  4  3.MPL/MOX  
    Highest scores from controls  509  167         
aUnlike % effectiveness, the lower the score the lower the resistance level and worm 
populations. Resistance score is a weighted mean of MPL, ML and BZLV R-alleles. The 
worm score includes host death and worm burden and is a weighted mean of the two species 
involved (see text); 
cMean death rate for lambs and ewes. 
 
 
Discussion 
 
Rotations between anthelmintic classes were within the annual sheep production system 
because this allows for greater flexibility than calendar-based (i.e. year-to-year) drench 
rotations. In some circumstances a drug with persistent activity may be required, while at 
most times a short-acting high efficacy treatment is the preferred option.
9 Rotating between 
drug classes on an annual calendar basis does not allow for this kind of flexibility. 
 
A key result was that a combination of all anthelmintic classes, including MPL, was the best 
option for delaying the development of anthelmintic resistance while achieving effective 
worm control. However, because of cost it is unlikely to be routinely applied for all ‘strategic’ 
or ‘tactical’ treatments on farms where high numbers of anthelmintic treatments are applied 
annually. In this situation it would be ideal for quarantine treatments. On farms where 
relatively few treatments are given annually adopting this combination strategy may be a 
practical and cost effective option, however, refugia then becomes a critical issue and it is 
vital to ensure some portion of the nematode population remains unselected.
9 
 
Despite the relatively high levels of resistance that were assumed for BZ and LEV in this 
study, they still played a useful role in helping to delay the development of resistance to a new 
anthelmintic class and the MLs. It has been suggested that whenever a combination product is 
used it is advisable to leave some stock untreated.
9 However, leaving some sheep untreated is 
a contentious issue because the advantage of reducing selection for resistance must be 
weighed against possible production losses, including deaths, in untreated animals in some 
regions and seasons. Because of the harsh variable climate in Australia, refugia is one issue 
that cannot be ignored and in many situations, leaving some sheep untreated may be the only 
way to provide a reliable source of unselected nematodes. This strategy is based on targeted 
treatment
15 of stock in poor condition or leaving some healthy animals untreated rather than 
treating the entire flock. It has been studied in the field
16-18 and investigated by computer 10 
 
simulation to optimise the percentage of adult stock that may be left untreated.
13 In WA, 
where there is little refugia as infective larvae on pasture during the hot-dry summer period, 
leaving 1-4% of adults untreated throughout the year greatly helped delay selection for 
resistance without compromising worm control. However, this was not the case in VIC
13 
where the question of whether it was better to give the new high efficacy drug as the first or 
second summer anthelmintic treatment was tested and results indicated this was not an 
important issue (data not shown). 
 
The simple single score developed here is an attempt to find a balance between providing 
effective nematode control and selecting for drug resistance. The weights used to determine 
the score were provided by expert opinion and will vary from place to place and over time, 
but this can be accommodated in spreadsheet computations as updated scores can be used as 
required. The final score encompasses multiple nematode species, short- and long-term 
nematode burdens and death rates in ewes and lambs, and development of resistance to MPL, 
ML and BZLV. As such, it contains a component for sustainability, which will be valued 
differently by producers. The score was also presented in Tables 4-6 as percentage 
effectiveness to control nematodes and delay resistance so that the contribution of these 
components to the total score can be easily assessed. Some graziers may be willing to accept 
some reduction in nematode control to preserve the efficacy of their anthelmintics and Tables 
4-6 provide a tool to help quantify such considerations. The ability of each option to control 
nematodes and delay drug resistance was presented as a percentage of the worst case 
situation. However, if for example ‘effectiveness to control worms’ was expressed as a 
percentage of the best nematode control option, rather than the untreated control simulation, 
then a more conservative result would be obtained. For example, in Table 4 options 
MPL+COM, MPL/COM and MPL/COM/MOX had ‘effectiveness to control worms’ of 94%, 
91% and 93%, and associated ‘mean worm scores’ of 40, 54 and 44, respectively, i.e. 
MPL/COM and MPL/COM/MOX are respectively 35% and 10% higher (worse) than the best 
nematode control option in this environment. Traditionally, in parasitology, efficacy of a drug 
or treatment regimen is expressed as a percentage improvement over untreated or negative 
controls, which is why the results were summarised this way. On the other hand, production 
studies often include uninfected control groups against which production penalties are 
measured. From the ‘worm scores’ in Tables 4-6 the loss of effectiveness from the best option 
can be estimated if preferred. 
 
The schedule set out in Table 3 for NSW was simplified in terms of grazing management and 
minimal anthelmintic treatments to control Haemonchus, i.e. suited to low risk areas. For 
environments or farms that have a history of high Haemonchus risk then reliance on a 
schedule that includes additional grazing management and/or a drug with persistent activity 
such as MOX was required. The assumptions made with regard to the efficacy and persistent 
activity of MOX against Haemonchus and Teladorsagia (Appendix 1) lead to MOX efficacy 
remaining relatively high (85%+) even when ML resistance is high and some but not all ML-
resistant incoming larvae are prevented from establishing in the host. 
 
Although the simulation model and summary score are complex to describe and implement 
they nevertheless represent a gross oversimplification of the biological situation which 
involves interactions between a number of parasite species, nutrition, management practices, 
weather, nematode and host genetics. As such they best help design broad strategies rather 
than rigidly define detailed management systems for particular sites. The broad 11 
 
recommendations from the model are generally consistent across the three states despite the 
differences in management and climate. Such findings: providing a source of refugia; using 
combinations; and rotating MPL with combination products can be tailored to suit the 
individual farmer’s needs. The aim was not to be prescriptive but provide a guide to assist 
decisions, which are ultimately based on the objective of the farming enterprise and its 
resources. 
 
The model was developed from limited climate and pasture data,
13 however, simulations were 
carried out using weather data from regions in WA, VIC and NSW where variations in 
climate and the timing of key management decisions occur. For example, some sheep 
producing regions of southern NSW have climate and management systems comparable to 
those simulated for VIC. Because of such limitations sheep producers should seek 
professional advice with regard to their specific sheep management and nematode control 
issues so that a suitable regimen can be adapted to their circumstances. It is important that all 
involved in the Australian wool industry work towards preserving the effective life of 
available anthelmintics. 
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Appendix 1 Simulating drug efficacy and selection for anthelmintic resistance. 
 
Table A1 provides the assumed efficacy for the anthelmintics against each species and 
genotype; worm genotypes are denoted SS, RS and RR to represent homozygote susceptible, 
heterozygote, and homozygote resistant genotypes, respectively. Because the model
5 can only 
simultaneously simulate the development of resistance in three drug groups, developing 
resistance was simulated for: 1. MPL; 2. ML and 3. BZ+LEV as a combination (BZLV), 
simulated as a single gene. For all drugs the time to resistance was the time taken for the R-
allele frequency to reach 50%. This was chosen as the initial R-allele level for BZLV was 
assumed to be 40%. 
 
1.  Monepantel: Resistance to MPL was assumed to be co-dominant; if in future resistance is 
discovered to be recessive then resistance will take longer to develop than predicted by the 
model and if dominant, resistance will occur in a shorter time frame. However, the results are 
calculated as the ‘relative time’ to resistance and therefore the precise mode of inheritance is 
less important as the ratio of time to resistance is compared not the estimated time (e.g. 
resistance to MPL may develop three times slower under one option by comparison with 
another option etc.). The R-allele frequency that in part determines the rate at which 
resistance develops to MPL was set so that resistance to MPL would develop in 10 years or 
less when MPL was used exclusively. For each management system, the R-allele frequency 
below which resistance to MPL did not develop at all in 20 years when MPL was used 
exclusively was also assessed. 
 
2.  Macrocyclic lactones: For Teladorsagia and Haemonchus MOX has usually demonstrated 
relatively high efficacy against ML-resistant genotypes; ABA efficacy against ML-resistant 
genotypes is less than MOX but greater than ivermectin.
9 Because ML resistance in 
Trichostrongylus is rare it was assumed to be recessive for both ABA and MOX. 
 
3.  BZ/LEV combinations: In all simulations BZ and LEV are only given as part of a 
combination treatment with ABA. For BZ and LEV, the efficacies given in Table A1 were 
used to calculate the efficacy of a combination BZLV treatment against individual genotypes 
as shown in Table A2. In Table A2 genotypes are depicted by setting B, b, L, l to represent 
resistant (upper case) and susceptible (lower case) alleles to BZ and LEV, respectively. To 
determine the ‘Actual Efficacy’ of a combination treatment in Table A2 the proportion of 
genotypes removed was calculated by assuming BZ and LEV were applied sequentially.
3 For 
example, given 100 Haemonchus worms with say genotype BbLL then 50% and 10% are 
killed by BZ and LEV, respectively (from Table A1), if assuming no synergy then 50 worms 
remain after the BZ is applied, then 5 (10%) of the remainder are removed by LEV to leave 
45 worms, i.e. 55% are removed. The average of the efficacy for BZ-LEV-genotypes with the 
total number of R-alleles <2, =2 and >2 was used to represent SS, RS and RR genotypes to 
BZLV in the simulations. That is, the mean efficacy given in Table A2 was used against 
BZLV-combination genotypes when BZLV was applied. To estimate the accuracy of this 
approximation BZ, LEV and ABA were simulated as separate independent genes using the 
efficacies from Table A1 for COM only treatments of sheep under a VIC management 
regimen. The same simulation was again run but with only two independent genes: one for 
BZLV using the ‘Average Efficacy’ from Table A2; and one gene for ABA as defined in 
Table A1. In both simulations the initial R-allele frequency was set at 40%, 40% and 3% for 
BZ, LEV and ABA, respectively for both worm species. Under the VIC regimen three 14 
 
paddocks were used and Table A3 shows the increase in percentage R-allele frequency over 
20 years on each paddock for each drug, worm and method of simulation. Results were 
similar for both methods with resistance developing slightly faster when BZ and LEV were 
simulated by a single gene than when simulated by two independent genes. Though imposing 
some limitations on simulated treatment options, i.e. BZ and LEV can not be applied 
independently but only in combination, Table A3 indicates using one gene for the BZ+LEV 
treatments provides a reasonable approximation to using two genes. This then allows MPL 
and ML resistance to each be simulated separately by different genes as the model provides a 
total of three genes for simulating the development of resistance. 
 
Tables A1-A3 for Appendix 
Table A1 Anthelmintic efficacy (proportion killed) against homozygote susceptible (SS), 
heterozygote (RS), and homozygote resistant (RR) worm genotypes. 
Drug  SS  RS  RR 
Haemonchus     
Monepantel  0.999  0.500  0.100 
Benzimidazole  0.999  0.500  0.100 
Levamisole  0.999  0.999  0.100 
Abamectin  0.999  0.804  0.190 
Moxidectin  0.999  0.999  0.873 
aMoxidectin L3
  0.95  0.55  0.55 
Teladorsagia     
Monepantel  0.999  0.500  0.100 
Benzimidazole  0.999  0.500  0.100 
Levamisole  0.999  0.500  0.100 
Abamectin  0.999  0.999  0.603 
Moxidectin  0.999  0.999  0.857 
aMoxidectin L3
  0.95  0.13  0.13 
Trichostrongylus     
Monepantel  0.999  0.500  0.100 
Benzimidazole  0.999  0.500  0.100 
Levamisole  0.999  0.500  0.100 
Abamectin  0.999  0.999  0.873 
Moxidectin  0.999  0.999  0.873 
aMoxidectin L3
  0.95  0.55  0.55 
aFor Haemonchus, Teladorsagia and Trichostrongylus persistent efficacy of moxidectin 
against incoming infective larvae was assumed to last for 32, 32 and 5 days respectively. 15 
 
Table A2 Proportion of different worm genotypes removed by a combination treatment of BZ 
and LEV. Genotypes are represented by B, b, L, l to indicate resistant (capital) and 
susceptible (lower case) alleles to BZ and LEV, respectively. 
Total    Haemonchus  Teladorsagia/Trichostrongylus 
number of   
aActual 
bMean 
aActual 
bMean 
R-Alleles  Genotype  efficacy  efficacy  efficacy  efficacy 
0  bbll  0.999999       0.999999   
1  bbLl  0.999999  0.999833     0.9995  0.999666 
1  Bbll  0.9995  for ‘SS’     0.9995  for ‘SS’ 
2  BbLl  0.9995       0.75   
2  BBll  0.9991  0.999233     0.9991  0.916067 
2  bbLL  0.9991  for ‘RS’     0.9991  for ‘RS’ 
3  BBLl  0.9991       0.55   
3  BbLL  0.55  0.5797     0.55  0.43 
4  BBLL  0.19  for ‘RR’     0.19  for ‘RR’ 
aThe actual efficacy was calculated by applying BZ and LEV sequentially to the given 
genotype using the efficacies given in Table A1. 
bThe mean efficacy is the average of the 
actual efficacies for genotypes with <2, =2 or >2 total R-alleles for BZ or LEV. The mean 
efficacies were used in the simulations to approximate efficacy of combined BZ and LEV 
when modelled as a single gene. 
 
Table A3 Increase in percentage BZ, LEV and ABA R-allele frequency over 20 years when 
simulated by two methods under VIC sheep management given COM treatments only of 
BZ+LEV+ABA. Paddocks 1, 2 and 3 were grazed by ewes, weaner lambs and ‘dry’ adult 
sheep, respectively; ewes were set stocked whilst weaners share pasture rotation with adult 
sheep. 
Worm  Simulation    Paddock  1    Paddock  2    Paddock  3 
species 
amethod  BZ  LEV  ABA  BZ  LEV  ABA  BZ  LEV  ABA 
Teladorsagia  1 gene  0.8  0.8  0.6  0.8  0.8  0.7  3.1  3.1  2.4 
Teladorsagia  2 genes  0.5  0.5  0.1  0.6  0.6  0.7  2.0  2.0  2.1 
Trichostrongylus  1 gene  0.6  0.6  0.2  0.0  0.0  0.0  6.0  6.0  1.6 
Trichostrongylus  2 genes  0.4  0.4  0.2  0.0  0.0  0.0  4.2  4.2  1.5 
aResistance to BZ and LEV was simulated using either one gene for both drugs (1 BZLV 
gene) or two independent genes one for each drug (2 genes). The initial R-allele frequency 
was set at 40%, 40% and 3% for BZ, LEV and ABA respectively for both worm species. For 
both methods resistance to ABA was simulated with a single independent gene. 
 